Thiobarbituric acid Clinical Trials

Size	Price	Qty
100mg	USD 79
1g	USD 397

Clinical Trials

Multiple clinical trials evaluate physiological and health parameters across conditions including oxidative stress, long COVID, bone loss, energy deficiency, and psychiatric disorders. Sponsored by academic institutions, university hospitals, and national research councils—such as the University of Thessaly, Brock University, and the University of Barcelona—these unphased protocols encompass completed, active not recruiting, enrolling by invitation, and withdrawn statuses. Specific investigations evaluate dietary and antioxidant interventions targeting blood redox status, as well as physical exercise programs for managing long COVID symptoms.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04380155	Withdrawn	Bone Loss\|Energy Supply; Deficiency	Brock University\|Natural Sciences and Engineering Research Council Canada	2023-09-20	Not Applicable
NCT05848518	Completed	Long COVID	Campus docent Sant Joan de Déu-Universitat de Barcelona\|Hospital de Mataró\|University of Barcelona	2023-05-15	Not Applicable
NCT05756842	Active not recruiting	Oxidative Stress	University of Thessaly	2023-03-06	Not Applicable
NCT05861544	Enrolling by invitation	Psychiatry	Organization Against Drugs (ΟΚΑΝΑ)\|University of Thessaly	2023-03-23	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Thiobarbituric acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Thiobarbituric acid selectively reacts with malondialdehyde, a primary biomarker of lipid peroxidation, forming a stable chromogenic adduct that quantifies cellular membrane degradation and oxidative damage. By facilitating the colorimetric detection of lipid peroxidation in biological systems, this assay serves as a critical indicator for evaluating systemic redox balance across trial conditions such as oxidative stress, long COVID, and psychiatric disorders.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).